CJC-1295 Side Effects and Safety: Water Retention, Numbness, Glucose, and What to Watch (2026)

CJC-1295 Side Effects: What the Evidence Actually Shows

CJC-1295 side effects include water retention, tingling in the extremities, and transient changes in glucose metabolism. These effects are mechanistically linked to elevated GH and IGF-1 signalling, are typically dose-dependent, and resolve with dose reduction or cessation in most documented cases.

CJC-1295 is a long-acting growth hormone-releasing hormone (GHRH) analog that binds to albumin for an approximate 8-day half-life, driving sustained pulsatile GH and IGF-1 secretion. Teichman et al. 2006 confirmed in healthy men aged 20–40 that doses of 60–90 mcg/kg preserved GH pulsatility while elevating trough GH and IGF-1 above baseline. That is the pharmacology working as intended. The question this guide answers is what happens when GH and IGF-1 rise beyond baseline and whether those changes carry meaningful risk.

This post addresses four specific concerns that appear repeatedly in clinical literature and user reports: water retention, peripheral numbness or tingling, glucose metabolism, and injection-site reactions. A fifth concern, regulatory status, underpins all of them.

Affiliate disclosure: This post contains a link to RealPeptides, a research-grade supplier. Underground Biohacking may earn a commission at no cost to you. Compounds discussed are for research purposes only.

Water Retention: The Primary Side Effect

Water retention is the most consistently reported side effect associated with GH-axis stimulation, and CJC-1295 is no exception. The mechanism is renal and well characterised.

Elevated IGF-1 increases plasma renin activity, which in turn activates the renin-angiotensin-aldosterone system (RAAS). Simultaneously, IGF-1 suppresses atrial natriuretic factor (ANF), a peptide hormone that promotes sodium excretion. The net result is sodium reabsorption in the renal tubules followed by secondary water retention. Hirschberg et al. 1999 demonstrated this mechanism directly in healthy adults administered IGF-1, noting measurable fluid and sodium retention via RAAS activation. Tönshoff et al. 1997 observed the same pattern with short-term GH administration in children, reporting that sodium retention occurs first and water retention follows as a secondary response.

The important clinical detail is time course. In most documented cases, these changes are transitory. Tönshoff et al. 1997 noted normalisation within 7 to 28 days of continued therapy as the body adapts. At higher GH doses, the response can be more acute: Gupta and Bhatt 2021 note that higher rhGH doses may produce edema and weight gain that typically disappears after dose reduction. In the CJC-1295 context, this argues for starting at a conservative dose rather than titrating upward aggressively.

Practical Signs to Watch

• Puffiness around the eyes or ankles on waking
• Ring tightness or shoe tightness that was not present before
• Scale weight increase of 1–3 kg in the first two weeks without dietary change
• Reduced definition despite no change in body fat

None of these alone confirm pathological retention, but tracking them against a baseline helps distinguish early-adaptation fluid shifts from a signal that warrants dose adjustment.

Numbness, Tingling, and Carpal Tunnel Risk

Peripheral tingling, most commonly in the hands and wrists, is reported with GH-axis elevation. The mechanism is tissue proliferation driven by IGF-1, which can increase synovial volume in the carpal tunnel and compress the median nerve. Toth et al. 2001 documented bilateral median neuropathy in an elite athlete self-administering GH, describing it as the first documented case of GH-induced carpal tunnel syndrome in an athletic population.

Gupta and Bhatt 2021 confirm that carpal tunnel syndrome is a recognised adverse effect at higher GH doses, and that symptoms typically resolve after dose reduction. The incidence with CJC-1295 specifically is not established from controlled trial data, but the mechanistic pathway is the same: CJC-1295 elevates GH and IGF-1, and IGF-1 drives the tissue changes responsible for nerve compression.

Who Carries More Risk

• Individuals with pre-existing carpal tunnel symptoms
• Those using CJC-1295 at higher doses without titration
• Users stacking CJC-1295 with a GHRP (which amplifies total GH pulse height)
• Those performing high-volume grip or wrist-loading training

Early intervention matters. Tingling that begins in the first two to four weeks and is accompanied by grip weakness or nighttime wrist pain warrants immediate dose reduction and evaluation. Waiting for symptoms to intensify before acting increases the time to resolution.

Glucose and Insulin: The Metabolic Question

GH is a counter-regulatory hormone for insulin. At supraphysiological concentrations, it reduces insulin sensitivity in peripheral tissues. This is well-established with pharmacological rhGH doses. The question for CJC-1295 is whether the more modest, pulsatile GH increases it produces carry the same metabolic risk.

The comparative data from tesamorelin, an FDA-approved GHRH analog with a closely related mechanism, is instructive. Stanley et al. 2015 administered tesamorelin to patients with type 2 diabetes over 12 weeks and found no significant alteration in insulin response or glycaemic control. The conclusion drawn was that GHRH analogs, by preserving physiological IGF-1 feedback and GH pulsatility, generate fewer metabolic disturbances than fixed-dose pharmacological GH. LiverTox 2018 does note glucose intolerance as a potential adverse event with GHRH analog therapy, particularly in individuals with pre-existing metabolic risk.

The practical implication: men with elevated fasting glucose, insulin resistance, or a family history of type 2 diabetes should monitor fasting glucose and consider HbA1c at baseline and at 8–12 weeks. This is not a reason to avoid the compound categorically, but it is a reason to measure rather than assume.

Injection-Site Reactions and Flushing

Subcutaneous injection of CJC-1295 can produce localised redness, warmth, and transient itching at the injection site. Teichman et al. 2006 documented injection-site reactions in their clinical cohort, describing them as mild and self-limiting. Facial flushing in the minutes following injection has also been noted, likely reflecting an acute vasodilatory response to the initial peptide dose. These reactions are generally low severity and tend to diminish with continued use as receptor desensitisation occurs at the local tissue level.

Regulatory Status and What It Means for Safety

CJC-1295 is not FDA-approved. It operates in the research compound gray market with the limited clinical trial oversight that status implies. Ramirez et al. 2026 characterise it as an unapproved peptide with a less rigorous safety evaluation than approved compounds, despite circulating safety profiles. This matters practically: the absence of a phase III trial means that rare adverse events may not yet be characterised, and purity standards across suppliers vary.

Quality sourcing is not a marketing consideration here. It is a safety consideration. Impurities or incorrect peptide sequences can produce effects unrelated to CJC-1295 pharmacology and make adverse event attribution difficult. For research context, RealPeptides provides third-party tested CJC-1295 with certificate of analysis documentation.

For more on the regulatory landscape of gray-market research peptides, see our post on safety of unapproved gray-market peptides.

Dosage Reference and Side-Effect Correlation

The clinical trial doses that established CJC-1295 pharmacology were 60 mcg/kg and 90 mcg/kg as single injections in healthy adults aged 20–40 (Teichman et al. 2006). Research-context dosing protocols derived from those findings and from GHRH analog comparisons typically reference the following ranges:

The dose-response relationship is direct: higher GH pulse amplitude means greater IGF-1 elevation, stronger renal sodium retention, and higher tissue IGF-1 exposure at the carpal tunnel. Starting at the conservative end of this range and observing for four weeks before any upward titration is the most risk-aware approach the literature supports.

For a detailed breakdown of how GHRH analogs drive GH pulse physiology, see our post on how GHRH analogs stimulate growth hormone.

Monitoring Protocol: What to Track and When

Because CJC-1295-specific clinical trial data in humans is sparse, the monitoring framework below is informed by GHRH analog comparator studies (particularly tesamorelin) and GH mechanism literature. It is the minimum a research-context user should consider.

Baseline (Before First Dose)

• Fasting glucose and HbA1c
• IGF-1 (serum, morning)
• Blood pressure
• Body weight (morning, fasted)
• Symptom baseline for grip strength and wrist comfort

Weeks 1–4

• Weekly body weight (morning, fasted) to quantify fluid retention trajectory
• Daily self-assessment for hand tingling or grip weakness
• Blood pressure at week 2 if water retention is symptomatic

Week 8–12

• Repeat IGF-1 to confirm response is within physiological range
• Repeat fasting glucose (HbA1c if pre-diabetic at baseline)
• Clinician review of findings before continuing

IGF-1 elevation beyond the upper end of the age-matched reference range is a signal to reduce dose, not a badge of optimal response. Supraphysiological IGF-1 is where the risk-to-benefit calculation changes.

Side-Effect Management: Practical Actions

Water Retention

Reduce sodium intake during the first two to three weeks. Ensure adequate hydration (the paradox of fluid restriction worsening retention is well established). If edema is clinically significant or blood pressure rises, reduce dose and consult a clinician. Most cases resolve within 7 to 28 days as the research literature indicates (Tönshoff et al. 1997).

Tingling and Early Carpal Tunnel Symptoms

Early intervention is critical. Do not wait for frank grip weakness. At first signs of persistent hand or wrist tingling, reduce dose. If symptoms do not improve within two weeks of dose reduction, cease use entirely and seek medical evaluation. Untreated median nerve compression from tissue oedema can progress.

Glucose Management

If fasting glucose is elevated at baseline or rises during the research period, reduce dose. Stacking CJC-1295 with compounds that have independent effects on insulin sensitivity amplifies this risk and is outside the scope of this guide. IGF-1 and glucose metabolism effects has a fuller treatment of the mechanisms involved.

The Comparison Context: CJC-1295 vs. Direct GH

A recurring question is whether CJC-1295 is safer than exogenous GH. The mechanistic argument in its favour is that GHRH analogs stimulate endogenous GH release and preserve the IGF-1 negative feedback loop, preventing the sustained supraphysiological IGF-1 concentrations seen with fixed-dose exogenous GH administration. Stanley et al. 2015 found the related GHRH analog tesamorelin did not alter insulin response in diabetic patients, a finding inconsistent with what would be expected from equivalent exogenous GH doses. The preserved pulsatility documented in Teichman et al. 2006 supports this mechanistic advantage.

That said, "fewer metabolic side effects than pharmacological GH doses" is not the same as "no side effects." The side effects documented above are real, dose-dependent, and in some cases (carpal tunnel) potentially progressive if unaddressed. The comparison to direct GH provides context, not reassurance.

Bibliography

1. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PubMed
2. Ramirez JA, et al. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. PubMed
3. Hirschberg R, et al. IGF-I administration induces fluid and sodium retention in healthy adults. Am J Physiol. 1999. PubMed
4. Tönshoff B, et al. Water and sodium retention during short-term administration of growth hormone to short normal children. Pediatr Nephrol. 1997. PubMed
5. Toth C, et al. Bilateral median neuropathy and growth hormone use: a case report. Arch Phys Med Rehabil. 2001. PubMed
6. Gupta V, Bhatt H. Renal effects of growth hormone in health and in kidney disease. Curr Opin Nephrol Hypertens. 2021. PubMed
7. Stanley TL, et al. Safety and metabolic effects of tesamorelin in patients with type 2 diabetes. Diabetes Care. 2015. PubMed
8. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Tesamorelin. NCBI Bookshelf. 2018. NCBI

This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice. Always work with a qualified clinician before making changes to your health protocol.